Churg Strauss Syndrome Market Size, Share, Growth, Trends, and Global Industry Analysis: By Route of Administration (Oral, Injectable), By Indication (Acute ischemic Stroke, Cerebral Insufficiency, Alzheimer's Disease, Attention Deficit-Hyperactive Disorder (ADHD), and Other Brain Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Forecast 2020-2031

Churg Strauss Syndrome Market size was valued at US$ 373.5 million in 2024 and is expected to reach US$ 508.3 million by 2031, growing at a significant CAGR of 20.3% from 2025-2031. Patients with Churg Strauss Syndrome are given prednisone, methylprednisolone, or another immunosuppressive corticosteroid drug, which is a generic pharmaceutical. The Five Factor Score (FFS) for each patient determines the medicine for Churg Strauss Syndrome. According to NORD, the estimated mean annual incidence of churg strauss syndrome is 2.4 individuals per million and can affect individuals of almost any age and has ranged from 15 to 70 years of age. Moreover, most the researchers say that the disease is undiagnosed and leads to many complications in the future years. However, lack of awareness reading autoimmune disorders and unfavorable reimbursement policies are expected to hinder the growth of the market over the future years.